Now that the Bioheart IPO has doubly surprised.
In fact, I’ll aim to make this a regular feature, because the IPO market is still a useful leading indicator for venture funding.. Now that the Bioheart IPO has doubly surprised everyone — first by happening at all, and second by coming out on such dreadful terms for the company — perhaps it’s time to take a closer look at exactly where the 2008 offering market for life-science companies stands.
Original text search at: venturebeat.com/index.php?tag=ipo